|
| 38050155 | Reproducibility and Accuracy of the PRIMARY Score on PSMA PET and of PI-RADS on Multiparametric MRI for Prostate Cancer Diagnosis Within a Real-World Database. | J Nucl Med | 2024 |
| 37945382 | Characterizing Normal Variant [<sup>68</sup>Ga]Ga-FAPI-46 Uptake in the Epididymis. | J Nucl Med | 2024 |
| 36863416 | Patterns of Failure in Men With Radiorecurrent Prostate Cancer: A Post Hoc Analysis of 3 Prospective Gallium 68 Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography Imaging Trials. | Int J Radiat Oncol Biol Phys | 2023 |
| 37562803 | Redesigned Curricula, Stringent Licensing Criteria, and Integrated Independence Are Conditions for a Bright Future for Nuclear Medicine in the United States. | J Nucl Med | 2023 |
| 37591547 | Do Bone Scans Overstage Disease Compared with PSMA PET at Initial Staging? An International Multicenter Retrospective Study with Masked Independent Readers. | J Nucl Med | 2023 |
| 37902861 | Effects of novel androgen receptor signaling inhibitors on PSMA PET signal intensity in patients with castrate-resistant prostate cancer: a prospective exploratory serial imaging study. | EJNMMI Res | 2023 |
| 37797974 | Tandem Isotope Therapy with <sup>225</sup>Ac- and <sup>177</sup>Lu-PSMA-617 in a Murine Model of Prostate Cancer. | J Nucl Med | 2023 |
| 37482512 | Presurgical <sup>68</sup>Ga-PSMA-11 Positron Emission Tomography for Biochemical Recurrence Risk Assessment: A Follow-up Analysis of a Multicenter Prospective Phase 3 Imaging Trial. | Eur Urol | 2023 |
| 37779132 | Associations of quantitative whole-body PSMA-PET metrics with PSA progression status under long-term androgen deprivation therapy in prostate cancer patients: a retrospective single-center study. | Eur J Hybrid Imaging | 2023 |
| 37678928 | Impact of <sup>68</sup>Ga-FAPI PET/CT on Staging and Oncologic Management in a Cohort of 226 Patients with Various Cancers. | J Nucl Med | 2023 |
| 37678927 | Prognostic Value of End-of-Treatment PSMA PET/CT in Patients Treated with <sup>177</sup>Lu-PSMA Radioligand Therapy: A Retrospective, Single-Center Analysis. | J Nucl Med | 2023 |
| 35776566 | Non-oncologic incidental uptake on FAPI PET/CT imaging. | Br J Radiol | 2023 |
| 37290800 | SNMMI Consensus Statement on Patient Selection and Appropriate Use of <sup>177</sup>Lu-PSMA-617 Radionuclide Therapy. | J Nucl Med | 2023 |
| 37321828 | PSMA-Negative Lesion Progression Under <sup>177</sup>Lu-PSMA Radioligand Therapy. | J Nucl Med | 2023 |
| 37321822 | [<sup>68</sup>Ga]Ga-FAPI-46 PET for Visualization of Postinfarction Renal Fibrosis. | J Nucl Med | 2023 |
| 37389447 | <sup>68</sup>Ga-FAPI-46 PET/CT Tracer Uptake in CT-diagnosed Intra-Abdominal Fat Necrosis. | Radiol Imaging Cancer | 2023 |
| 37055221 | Looking at the Future of Prostate Cancer Treatment: A Conversation Between Michael Morris, Jeremie Calais, and Johannes Czernin. | J Nucl Med | 2023 |
| 37246997 | Joint EANM/SNMMI procedure guideline for the use of <sup>177</sup>Lu-labeled PSMA-targeted radioligand-therapy (<sup>177</sup>Lu-PSMA-RLT). | Eur J Nucl Med Mol Imaging | 2023 |
| 37146173 | FAPI PET Signal in Hibernoma Reflects FAP Expression in Tumor Vasculature Cells. | Clin Nucl Med | 2023 |
| 37269841 | Health-related quality of life and pain outcomes with [<sup>177</sup>Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a multicentre, open-label, randomised, phase 3 trial. | Lancet Oncol | 2023 |
| 37203346 | Editorial Comment. | J Urol | 2023 |
| 37333052 | Fibroblast Activation Protein Expression in Sarcomas. | Sarcoma | 2023 |
| 37230533 | A VISION Substudy of Reader Agreement on <sup>68</sup>Ga-PSMA-11 PET/CT Scan Interpretation to Determine Patient Eligibility for <sup>177</sup>Lu-PSMA-617 Radioligand Therapy. | J Nucl Med | 2023 |
| 37230532 | Obstructive Sialadenitis from Oral Squamous Cell Carcinoma: [<sup>68</sup>Ga]Ga-FAPI-46 PET-Positive and [<sup>18</sup>F]FDG PET-Negative. | J Nucl Med | 2023 |
| 37432081 | Response Evaluation Criteria in PSMA PET/CT (RECIP 1.0) in Metastatic Castration-resistant Prostate Cancer. | Radiology | 2023 |
| 36997329 | PSMA PET Tumor-to-Salivary Gland Ratio to Predict Response to [<sup>177</sup>Lu]PSMA Radioligand Therapy: An International Multicenter Retrospective Study. | J Nucl Med | 2023 |
| 37358989 | Focal therapy of prostate cancer: Assessment with prostate-specific membrane antigen (PSMA) imaging. | Urol Case Rep | 2023 |
| 37428216 | Is PSMA PET/CT cost-effective for the primary staging in prostate cancer? First results for European countries and the USA based on the proPSMA trial. | Eur J Nucl Med Mol Imaging | 2023 |
| 36725249 | SNMMI Procedure Standard/EANM Practice Guideline for SSTR PET: Imaging Neuroendocrine Tumors. | J Nucl Med | 2023 |
| 36443902 | Exploring new frontiers in prostate cancer research:Â Report from the 2022 Coffey-Holden prostate cancer academy meeting. | Prostate | 2023 |
| 36581376 | Incidental Focal <sup>68</sup>Ga-FAPI-46 Uptake in a Urachal Remnant: A Potential Pitfall Mimicking a Malignant Peritoneal Lesion. | J Nucl Med | 2023 |
| 36935345 | Second Version of the Prostate Cancer Molecular Imaging Standardized Evaluation Framework Including Response Evaluation for Clinical Trials (PROMISEÂ V2). | Eur Urol | 2023 |
| 36870853 | Transcriptomic Heterogeneity in High-risk Prostate Cancer and Implications for Extraprostatic Disease at Presentation on Prostate-specific Membrane Antigen Positron Emission Tomography. | Eur Urol Oncol | 2023 |
| 36604326 | PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0. | Eur J Nucl Med Mol Imaging | 2023 |
| 36933329 | Incorporating radioligand therapy in clinical practice in the United States for patients with prostate cancer. | Cancer Treat Rev | 2023 |
| 36635088 | Developing a Patient-Reported Outcome Measure for Radionuclide Therapy for Prostate Cancer. | J Nucl Med | 2023 |
| 36797449 | LUNAR: a randomized Phase 2 study of <sup>177</sup> Lutetium-PSMA Neoadjuvant to Ablative Radiotherapy for Oligorecurrent Prostate Cancer (clinical trial protocol). | BJU Int | 2023 |
| 36759200 | [68]Ga-PSMA PET/CT-Based Atlas for Prostate Bed Recurrence After Radical Prostatectomy: Clinical Implications for Salvage Radiation Therapy Contouring Guidelines. | J Nucl Med | 2023 |
| 36863780 | The <sup>177</sup>Lu-PSMA-617 (Pluvicto) Supply Problem Will Be Solved by Competition. | J Nucl Med | 2023 |
| 32958451 | Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Compared with Conventional Imaging for Initial Staging of Treatment-naïve Intermediate- and High-risk Prostate Cancer: A Retrospective Single-center Study. | Eur Urol Oncol | 2022 |
| 35772954 | More Unacceptable Denials: Now It's PSMA-Targeted PET/CT Imaging. | J Nucl Med | 2022 |
| 35649664 | How Many Theranostics Centers Will We Need in the United States? | J Nucl Med | 2022 |
| 35767071 | Measuring response in metastatic castration-resistant prostate cancer using PSMA PET/CT: comparison of RECIST 1.1, aPCWG3, aPERCIST, PPP, and RECIP 1.0 criteria. | Eur J Nucl Med Mol Imaging | 2022 |
| 35609224 | Predictors and Real-World Use of Prostate-Specific Radioligand Therapy: PSMAÂ and Beyond. | Am Soc Clin Oncol Educ Book | 2022 |
| 35422442 | Novel Framework for Treatment Response Evaluation Using PSMA PET/CT in Patients with Metastatic Castration-Resistant Prostate Cancer (RECIP 1.0): An International Multicenter Study. | J Nucl Med | 2022 |
| 36182983 | Comparison of PSMA-TO-1 and PSMA-617 labeled with gallium-68, lutetium-177 and actinium-225. | EJNMMI Res | 2022 |
| 33602654 | Identifying the Best Candidates for Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography as the Primary Staging Approach Among Men with High-risk Prostate Cancer and Negative Conventional Imaging. | Eur Urol Oncol | 2022 |
| 35099620 | Initial evaluation of [<sup>18</sup>F]-FACBC for PET imaging of multiple myeloma. | EJNMMI Res | 2022 |
| 35273096 | Outcome of Patients with PSMA PET/CT Screen Failure by VISION Criteria and Treated with <sup>177</sup>Lu-PSMA Therapy: A Multicenter Retrospective Analysis. | J Nucl Med | 2022 |
| 35175289 | PSMA PET in Prostate Cancer-A Biomarker or a Surrogate End Point?-Reply. | JAMA Oncol | 2022 |